Medical Doctor Program year 2025 Reported 2023–2025 Source: CMS Open Payments, 2026 publication

Ryan Kim

Ophthalmology Duncanville, TX Medical Doctor

NPI 1497384341 CMS profile 11627639

388 E Highway 67, Duncanville, TX 75137

Open in the dashboard

General payments

$3,725

61 records reported · program years 2023–2025

Research payments

$0

Paid to them · None reported · program years 2023–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ryan Kim of Duncanville, TX is reported in the CMS Open Payments database as having received $3,725 across 61 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 74th percentile of Ophthalmology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,475 37
2024 General $987 23
2023 General $262 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ryan Kim
  • Ophthalmology median
  • Middle half of Ophthalmology
  • National median

In program year 2025, general payments to Ryan Kim were reported at $2,475. Among 13,034 Ophthalmology profiles paid that year, the median was $384 and the middle half received between $136 and $917.

Show as a table
Year Ryan Kim Ophthalmology median Middle half National median
2019 $0 $258 $104–$655 $163
2020 $0 $126 $45–$321 $114
2021 $0 $205 $76–$534 $132
2022 $0 $266 $100–$678 $149
2023 $262 $308 $117–$745 $160
2024 $987 $340 $127–$846 $164
2025 $2,475 $384 $136–$917 $169

Breakdown

Who paid General payments · program years 2023–2025
  1. AbbVie, Inc. $1,394 10 payments
  2. Alcon Vision LLC $910 16 payments
  3. Sight Sciences, Inc. $347 7 payments
  4. Amgen Inc. $281 5 payments
  5. Johnson & Johnson Surgical Vision, Inc. $262 1 payment
  6. TissueTech, Inc. $187 8 payments
  7. Tarsus Pharmaceuticals, Inc. $120 4 payments
  8. Glaukos Corporation $76 2 payments
  9. Bausch & Lomb Americas Inc. $39 2 payments
  10. Harrow Eye, LLC $34 2 payments
  11. Other $74 4 payments

Every payment, record by record

What the payments were for General payments · program years 2023–2025
  1. Food and Beverage $2,775 60 payments
  2. Consulting Fee $950 1 payment
Products named General payments · program years 2023–2025
  1. DURYSTA $1,071 5 payments
  2. OMNI SURGICAL SYSTEM $347 7 payments
  3. XEN GLAUCOMA TREATMENT SYSTEM $322 4 payments
  4. TEPEZZA $281 5 payments
  5. Clareon PanOptix Pro $274 2 payments
  6. SION SURGICAL INSTRUMENT $274 2 payments
  7. LIPIFLOW SYSTEM ACTIVATOR (DISPOSABLE) $262 1 payment
  8. LIPIFLOW SYSTEM ACTIVATOR II (DISPOSABLE $262 1 payment
  9. MEIBOMIAN GLAND EVALUATOR $262 1 payment
  10. LIPIVIEW OCULAR SURFACE INTERFEROMETER $262 1 payment
  11. Other $1,385 39 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

474

Median for Ophthalmology: 891

Drug cost

$10,215

Median for Ophthalmology: $68,233

Branded share of claims

25.7%

Median for Ophthalmology: 29.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Prednisolone Acetate Generic 93 $2,924
Loteprednol Etabonate Generic 13 $1,668
Brimonidine Tartrate Generic 54 $1,585
Latanoprost Generic 142 $1,302
Dorzolamide-Timolol Dorzolamide Hcl/Timolol Maleat Brand 81 $831
Ketorolac Tromethamine Generic 32 $760
Moxifloxacin Moxifloxacin Hcl Brand 28 $696
Dorzolamide Hcl Generic 18 $304
Bacitracin-Polymyxin Bacitracin/Polymyxin B Sulfate Brand 13 $145

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 16 billing codes

Paid by Medicare

$19,323

Medicare's payments for the services billed

Medicare patients

137

Average age 75

Services billed

271

89 women, 48 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 54%
Diabetes 42%
Chronic kidney disease 28%
Ischemic heart disease 26%
Heart failure 18%
Osteoporosis 18%
Atrial fibrillation 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TEPEZZA
  • Amgen Inc. $225
$225 — —
LUMIGAN
  • AbbVie, Inc. $46
$46 — —
XDEMVY
  • Tarsus Pharmaceuticals, Inc. $40
$40 — —
DURYSTA
  • AbbVie, Inc. $32
$32 — —
Rocklatan
  • Alcon Vision LLC $21
$21 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

61 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Ophthalmology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record